Abstract:Abstract PIK3CA, encoding the active alpha isoform of PI3K, is the second most commonly mutated gene in cancer leading to aberrant PI3K/AKT/mTOR signaling and increased protein translation, glucose metabolism, cellular proliferation, survival and migration. Some 4-25% of gastric cancers (GC) display activating PIK3CA mutations including 80% of the EBV-associated GC subset. Small molecules including pan-PI3K, dual PI3K/mTOR, and pan-AKT inhibitors have shown only moderate clinical success, primarily due to high toxicity and off target effects. Even isoform specific PI3K inhibitors, such as PI3Kα inhibitors, have displayed similar clinical problems. Importantly, PI3Kα mutation-selective inhibitors are on the horizon and will be key for treatment of PIK3CA mutant tumors. However, single agent drug resistance is still an anticipated clinical problem and both intrinsic and acquired resistance will affect success of new drugs. There has been a concerted effort to define mechanisms of resistance as well as identify synergistic drug combinations. In this study we aimed to identify mechanisms of sensitivity and resistance to the PI3Kα-specific inhibitor, BYL719, in PIK3CA mutant gastric cancers by using a CRISPR/Cas9-based screening approach. We found that loss of either NEDD9 or BCL-XL was synergistic with BYL719 and led to increased cell cycle arrest and apoptosis, respectively. In addition to identifying these sensitizer genes, the screening approach allowed us to model intrinsic resistance, and we discovered that knockout of the translation and transcription factor, CBFB, conferred resistance to BYL719. To model acquired resistance, we cultured cells in increasing concentrations of BYL719 over three months and generated clones that were resistant when compared to parental cells. We found that in the clones with acquired resistance, CBFB was significantly down-regulated at the protein and RNA level suggesting a conserved mechanism of drug resistance. We found that CBFB loss led to up-regulation of the serine/threonine protein kinase PIM1, which can phosphorylate and activate several of the same downstream substrates as AKT thereby maintaining pathway activity in the presence of PI3Kα inhibition. Furthermore, a pan-PIM inhibitor re-sensitized both CBFB knockout and acquired resistant cells to BYL719. In the TCGA clinical dataset, we found that CBFB is over-expressed in gastric tumors, specifically in the EBV-associated subset, compared to normal tissue and is significantly over-expressed in PIK3CA mutant compared to wild type tumors. Consistently, we found that PIM1 expression displays the inverse phenotype. These data suggest that while CBFB loss is a key step in the development of PI3Kα inhibitor resistance, PIK3CA mutant gastric tumors may be good candidates for clinical success with BYL719 alone and resistance could be prevented with combination with a PIM kinase inhibitor. Citation Format: Lyla Stanland, Hazel Ang, Jacob Hoj, Yunqiang Chu, Patrick Tan, Kris Wood, Micah Luftig. Identification of novel regulators of response to PI3Ka inhibition in PIK3CA mutant gastric cancer. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4949.

Csig-30. Exploring The Role Of Capicua (Cic) In Resistance Mechanisms Of Mek Inhibitors In Glioblastoma

BET Protein Inhibition Evidently Enhances Sensitivity to PI3K/mTOR Dual Inhibition in Intrahepatic Cholangiocarcinoma

CIC reduces xCT/SLC7A11 expression and glutamate release in glioma

Abstract 1720: MSK1 Mediates PI3K Inhibition Resistance by Induction of Β-Catenin Phosphorylation in Glioblastoma

Csig-25. Mapk/Erk Signaling In Gliomas Modulates Interferon Responses, Promotes Tumor-Microglia Crosstalk, And Confers Susceptibility To Anti-Pd-1 And Anti-Ctla-4 Immunotherapy

DDDR-18. SINGLE-CELL FUNCTIONAL GENOMIC ANALYSIS OF PHARMACOLOGIC RESPONSES IN NF1 MUTANT GLIOBLASTOMA REVEALS DISTINCT MECHANISMS OF ACTION FOR MEK AND SHP2 INHIBITION

Protein kinase Cι and SRC signaling define reciprocally related subgroups of glioblastoma with distinct therapeutic vulnerabilities

Capicua suppresses YAP1 to limit tumorigenesis and maintain drug sensitivity in human cancer

SRC inhibition enables formation of a growth suppressive MAGI1-PP2A complex in isocitrate dehydrogenase-mutant cholangiocarcinoma

Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulation

DDDR-10. MYELOID CELLS COORDINATELY INDUCE GLIOMA CELL-INTRINSIC AND -EXTRINSIC PATHWAYS FOR CHEMORESISTANCE VIA GP130 SIGNALING

Ribosomal S6 protein kinase 4 promotes resistance to EZH2 inhibitors in glioblastoma

Targeting BMK1 Impairs the Drug Resistance to Combined Inhibition of BRAF and MEK1/2 in Melanoma.

Dddr-39. Pi3 Kinase And Checkpoint Inhibition: A Potentially Novel Therapeutic Strategy For Glioblastoma (Gbm)

Epigenetic Suppression of EGFR Signaling in G-CIMP+ Glioblastomas.

Ccrg-01. Myt1 Blockade As A Novel Glioma Therapeutics Through Abrogatiing Of The G2/M Cell Cycle Checkpoint

Abstract 4949: Identification of novel regulators of response to PI3Ka inhibition in PIK3CA mutant gastric cancer

Csig-13. Targeting Genetic Dependencies Exposes Diffuse Midline Glioma Cell Of Origin Vulnerabilities

EXTH-39. BIOMARKER DRIVEN TARGETING OF RECURRENT IDH MUTANT GLIOMA WITH ABEMACICLIB

Transcriptional CDK Inhibitors CYC065 and THZ1 Induce Apoptosis in Glioma Stem Cells Derived from Recurrent GBM